SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the main focus, with traders debating whether guidance can clear a high bar as AI-linked stocks face pressure. Some expect strong growth to support the shares, while others warn that even a beat may disappoint given the valuation; the stocks recent decline has sharpened that divide.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles shares have sharply reversed an Investor Day rally, with traders focused on whether its AI infrastructure backlog can justify heavy spending and debt despite managements cash-flow and capital-discipline outlook. The debate is split between bulls who view the buildout as a long-term growth opportunity and bears who question customer funding, backlog conversion, and the stocks weakness amid broader tech-sector pressure.

Cash Cat (CASHCAT) is a cryptocurrency launched in 2026and operates on the Robinhood Chain platform. Cash Cat has a current supply of 1,000,000,000. The last known price of Cash Cat is 0.0938856 USD and is up 2.53 over the last 24 hours. It is currently trading on 318 active market(s) with $8,318,268.61 traded over the last 24 hours. More information can be found at https://cashcattoken.xyz/.

Cash Cat

Cash Cat is drawing attention after a sharp, volatile rally on the Robinhood network, with traders pointing to exchange listingsincluding Upbitas a catalyst and watching for further momentum. Bullish holders frame dips as accumulation and speculate about a short squeeze, while skeptics call the moves pump-and-dump behavior and warn that gains have repeatedly faded.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces announced acquisition of customer-engagement software company Braze has put the stock under pressure, with traders questioning the cost and potential returns while others see a strategic boost to its AI and marketing products. The deal debate is unfolding against broader concerns that AI could disrupt traditional SaaS businesses.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to a 52-week high has traders focused on the upcoming Q3 report and whether BRIUMVIs sales momentum will support the companys growth outlook. Bullish call-option activity and high-short-interest chatter are fueling squeeze speculation, while buyout talk remains unconfirmed.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

Liquidias settlement with United Therapeutics resolved the companies pending lawsuits and keeps YUTREPIA on the market for PAH, while giving up the PH-ILD indication. Traders are reacting to the reduced risk of a broader sales interruption with optimism about a rebound and potential short covering, while others focus on the lost market opportunity and substantial settlement payments as risks to future growth and cash.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,180,209.38070502. The last known price of Ethereum is 2,270.17304981 USD and is up 0.59 over the last 24 hours. It is currently trading on 14230 active market(s) with $5,193,092,001.43 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Discussion centers on the reported multibillion-dollar Binance hack and its potential spillover to Ethereum and broader crypto markets. Traders are split between fearing further selling and lost exchange confidence, and viewing the selloff as a buying opportunity amid claims Binance will cover customer losses.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Discussion centers on claims that POET optical engines were featured in Foxconns photonics ecosystem, which traders view as validation of the existing FIT collaboration and possible precursor to purchase orders. Others caution that a demo does not establish commercial shipments, and frustration over limited order and revenue disclosures is prominent as investors look to earnings for evidence of execution.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on broad-market volatility and the Dows relative strength versus tech-heavy indexes, with traders debating whether the Dow can hold support or join a broader decline. Macro concernsincluding rising yields, inflation, and Iran-related oil and geopolitical riskscompete with bullish calls for a continued rally.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is being swept up in a semiconductor selloff as traders question whether hyperscalers heavy AI spending can generate adequate returns and worry that any capex slowdown could hit custom-chip orders. Some see AVGO as collateral damage despite ongoing AI commitments, including Anthropic-related demand, while others argue its concentrated customer base leaves it exposed if spending falters.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inhibrx Announces Participation in Upcoming Scientific Conferences

Inhibrx Announces Participation in Upcoming Scientific Conferences Inhibrx Announces Participation in Upcoming Scientific ConferencesPR NewswireSAN DIEGO, Oct. 13, 2026SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage...

Wednesday 9/9 Insider Buying Report: INBX, AMR

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

At Inhibrx Biosciences, a filing with the SEC revealed that on Tuesday, Chief Execu...

Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates

Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.read more...

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study PR Newswire SAN DIEGO, Sept. 8, 2026 First OX40 agonist to...

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study PR Newswire SAN DIEGO, Sept. 4, 2026 Event to be webcast live...

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Reports Second Quarter 2026 Financial Results Inhibrx Reports Second Quarter 2026 Financial Results PR Newswire SAN DIEGO, Aug. 13, 2026 SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the...

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million PR Newswire SAN DIEGO, July 16, 2026 SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx...

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice

Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma PR Newswire SAN DIEGO, June 15, 2026 No filing review issues identified by FDA with PDUFA...

Inhibrx Reports First Quarter 2026 Financial Results

Inhibrx Reports First Quarter 2026 Financial Results Inhibrx Reports First Quarter 2026 Financial Results PR Newswire SAN DIEGO, May 14, 2026 SAN DIEGO, May 14, 2026 /PRNewswire/ -- Inhibrx...

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Inhibrx Biosciences Inc.

INBX Stock Hit Record Highs: Cancer Therapies Reportedly Draw Big Pharma Interest

Equity

Neutral Sentiment

<ul><li>The therapy, which is being tested alone and in combination with Keytruda, a prescription immunotherapy, could be valued at over $8 billion, according to the report.</li><li>Inhibrx Biosciences could also spin off INBRX-106, along with another experimental cancer drug, into a separate entity.</li><li>The biotech firm reported promising interim data from its Phase 1/2 trial for advanced colorectal cancer on Tuesday.</li></ul>Shares of Inhibrx Biosciences (INBX) surged more than 40% on Wednesday to an all-time high, following reports of potential deal interest in its cancer pipeline, adding to momentum from encouraging early-stage colorectal cancer trial results.<h2>All Eyes On INBRX-106</h2>According to a Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-sources-say-2026-04-22/">report</a> on Wednesday,&nbsp;Inhibrx Biosciences has attracted early-stage interest from major drugmakers including Merck &amp; Co. (MRK), and Ono Pharmaceutical, for its experimental drug INBRX-106.The therapy, which is being tested alone and in combination with Keytruda, a prescription immunotherapy, could be valued at over $8 billion if trials confirm its potential to boost treatment response rates.The biotech firm could also spin off INBRX-106, along with another experimental cancer drug, into a separate entity that could be worth over $9 billion if trials are successful.<h2>New Cancer Drug Shows Promise</h2>Meanwhile, its second key asset, Ozekibart, is also gaining traction after Inhibrx Biosciences reported interim Phase 1/2 data for advanced colorectal cancer, showing promising results in pretreated patients.Among 45 patients, the treatment achieved a 20% response rate, well above the typical 1% - 6% seen with standard therapies. Nearly half of these responses lasted more than six months. The median progression-free survival was 5.5 months, and 42% of patients remained progression-free at 6 months.The therapy also showed a manageable safety profile, with mostly mild to moderate side effects such as diarrhea, fatigue, and nausea. Inhibrx plans to meet with the U.S. Food and Drug Administration (FDA) later this year to discuss advancing the treatment into late-stage trials.<h2>INBX Stock: How Did Retail Traders React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/INBX">INBX</a> turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes.One user noted “very strong data” from the Ozekibart trial.<stembedurl>https://stocktwits.com/BullStockpicks1/message/650960093</stembedurl>Another user was bullish about the firm’s prospects.<stembedurl>https://stocktwits.com/Terzman/message/650834526</stembedurl>Year-to-date, the stock has gained around 5%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

Inhibrx Biosciences has attracted early-stage interest from major drugmakers including Merck & Co. and Ono Pharmaceutical, for its experimental drug INBRX-106, according to a Reuters report.

INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play 

Inhibrx Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$71.78
Prev Close	$73.65
Open	$72.04
Dividend Yield	0.00%
50-Day Moving Average	$102.34
Beta	1.19
Avg. Volume	353,779.68
PE Ratio	-8.09

52-Week High	$155.29
52-Week Low	$57.30
Market Capitalization	$1.06B
EPS (Annual)	-$9.04
Price to Book	-19.93
Revenue Per Employee	$11,818.18

Feed

News

Sentiment

Earnings

Fundamentals

Info

INBX Fundamentals